FILTER

Refine your search with the following facets to narrow down your results.

18 Current news of Oncolytics Biotech

Oncolytics Biotech Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial

27-Apr-2010 - Oncolytics Biotech Inc. announced that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, ...

clinical trials neurosurgery radiation +1

Oncolytics Biotech Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy

12-Apr-2010 - Oncolytics Biotech Inc. announced that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. ...

cancer therapy immunology inhibitors +1

Oncolytics Biotech Inc. Appoints Senior Vice President, Global Licensing and Business Development

15-Dec-2009 - Oncolytics Biotech Inc. announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development. In his 32-year career, Dr. Warrander has held a number of positions within the biotechnology and pharmaceutical industries. He held a number ...

AstraZeneca biochemistry biotechnology +3

Oncolytics Biotech Inc. Announces Issuance of 33rd U.S. Patent

29-Oct-2009 - Oncolytics Biotech Inc. announced that it has been granted its 33rd U.S. Patent, No. 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic ...

chemotherapy neck cancer platinum

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients

04-Sep-2008 - Oncolytics Biotech Inc. announced that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer ...

chemotherapy clinical trials food +6

Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN/Docetaxel Trial

13-Aug-2008 - Oncolytics Biotech Inc. has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, ...

chemotherapy clinical trials toxicity

Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin

16-May-2008 - Oncolytics Biotech Inc. announced that that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with ...

clinical trials neck cancer

Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent

31-Jan-2008 - Oncolytics Biotech Inc. has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses." The claims describe methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses ...

herpes simplex oncolytic viruses stem cells +2

Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent

06-Sep-2007 - Oncolytics Biotech Inc. announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated cancers from developing drug resistance to ...

chemotherapy drug resistance

Oncolytics Biotech Inc. Announces Issuance of Patent for Treatment of Cellular Proliferative Disorders

09-Aug-2007 - Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,252,817 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias ...

herpes simplex viruses